Pharmaceutical Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld

Share Article

Pharmaceutical product manufacturers are evolving as patents for key products expire and the global industry undergoes rationalisation. For this reason, industry research firm IBISWorld has updated its report on the Pharmaceutical Product Manufacturing industry in Australia.

IBISWorld Market Research

IBISWorld Market Research

Industry players will adopt new business models as key drugs lose patent protection

The Pharmaceutical Product Manufacturing industry is dominated by major global pharmaceutical groups, although only a small number are engaged in secondary or actives manufacturing (active pharmaceutical ingredients), with an increasing number involved in just the later stages of the manufacturing process such as dispensing, packaging and the fill and finish stage. A large number of players also restrict their activities in Australia purely to distribution. In 2012-13, industry revenue is expected to decline by 2.1% as various internal and external factors take their toll. The industry is forecast to generate revenue of $9.34 billion in 2012-13, up by an annualised 0.9% over the past five years. According to IBISWorld industry analyst Kosta Lev, “domestic demand will be greater than revenue in 2012-13, highlighting the dominant role that imports play in the industry”. While the industry is a net importer, it is also one of Australia's largest high-technology exporters.

The industry is deemed to have a medium level of concentration, with the top four players – Pfizer Australia Holdings Pty Limited, GlaxoSmithKline Holdings Pty Ltd, AstraZeneca Pty Limited and Sanofi-Aventis Australia Pty Limited – accounting for a significant share of the local market. “This partly reflects the number of mergers that have occurred in the past few years”, says Lev. Given the highly globalised nature of the industry, this will continue to rise gradually in line with increasing concentration on the world stage.

In the next five years, the Pharmaceutical Product Manufacturing industry is expected to continue its gradual transformation process in view of slight revenue growth, declining research and development (R&D) productivity, increasing competitive pressures and rising safety concerns. Continued global industry rationalisation may also have implications for the level of pharmaceutical manufacturing and R&D undertaken in Australia. The industry will be affected by the expiration of patent protection for some of the world's key drugs between 2011 and 2015. This means that the pressure for change will escalate as major players lose exclusive manufacturing rights to some of the most profitable drugs in history. This will result in the adoption of new business models as industry participants seek to evolve in order to ensure their continued survival.

For more information, visit IBISWorld’s Pharmaceutical Product Manufacturing report in Australia industry page.

Follow IBISWorld on Twitter:!/ibisworldau

IBISWorld industry Report Key Topics

The Pharmaceutical Product Manufacturing industry comprises companies that manufacture various medicinal and pharmaceutical products, including drugs, medicines (including herbal medicines), medicinal chemicals as well as nappies and feminine hygiene products. Industry products are then either distributed by the manufacturer or via wholesalers to hospitals, pharmacies and other retail outlets such as supermarkets.

Industry Performance
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle
Products & Markets
Supply Chain
Products & Services
Major Markets
International Trade
Business Locations
Competitive Landscape
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Basis of Competition
Barriers to Entry
Industry Globalisation
Major Companies
Operating Conditions
Capital Intensity
Technology & Systems
Revenue Volatility
Regulation & Policy
Industry Assistance
Key Statistics
Industry Data
Annual Change
Key Ratios

About IBISWorld Inc.
Recognised as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every Australian industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Melbourne, IBISWorld serves a range of business, professional service and government organisations through more than 10 locations worldwide. For more information, visit or call (03) 9655 3886.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gavin Smith
(310) 490-5973
Email >
Visit website